Fountain Healthcare Partners

Founded 2008
Founders Aidan King Manus Rogan


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 30
Average round size
The average size of a deal this fund participated in
Portfolio companies 21
Rounds per year 2.31
Lead investments 9
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 6
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Medical Device
  • Therapeutics

The leading representative office of defined VC is situated in the Dublin. The fund was located in Europe if to be more exact in Ireland.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Fountain Healthcare Partners, startups are often financed by Enterprise Ireland, Seroba Life Sciences, Longitude Capital. The meaningful sponsors for the fund in investment in the same round are Enterprise Ireland, Novartis Venture Fund, Longitude Capital. In the next rounds fund is usually obtained by Enterprise Ireland, Sunstone Life Science Ventures, Roche Venture Fund.

Among the various public portfolio startups of the fund, we may underline Inflazome, Opsona, Amarin For fund there is a match between the country of its foundation and the country of its the most frequent investments - Ireland. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Biopharma. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

The current fund was established by Aidan King, Manus Rogan. The overall number of key employees were 4.

The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2014. Considering the real fund results, this VC is 22 percentage points more often commits exit comparing to other organizations. When the investment is from Fountain Healthcare Partners the average startup value is 50-100 millions dollars. The fund is constantly included in 2-6 investment rounds annually. Comparing to the other companies, this Fountain Healthcare Partners performs on 10 percentage points less the average number of lead investments. Deals in the range of 10 - 50 millions dollars are the general things for fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Fountain Healthcare Partners:
Typical Co-investors
Fountain Healthcare Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Fountain Healthcare Partners:

Funds with similar focus

Funds from Ireland, Dublin
Funds with similar focus located in Ireland, Dublin:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Arizona Tech Investors United States, Mesa
Neulogy Ventures Slovakia (Slovak Republic), Bratislava
Norner Verdandi Norway, Stathelle
Shell Foundation United Kingdom, London
Fort Washington Capital Partners Group United States, Cincinnati
Turnaround Management Association United States, Chicago
NKB Germany, Binswangen
Partners Path Investments United States, New York
Marwit United States, Newport Beach
Enfuro Ventures -
Capital Now -
Yunnan Changtai Touzi China, Kunming
PiSA Biopharm United States, Albany
Sun On Investment China, Guangzhou
ZQ Capital -
Hyperwise Ventures Israel, Tel Aviv
Furui Jiacheng Investment Management China, Songjiang
Weltbild Germany, Augsburg
Wenhong Enterprise Management China, Xian Shi
Cristofoli Contracting -

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

NeRRe Therapeutics

Health Care
$27M07 Jul 2021 United Kingdom, " United Kingdom"}

Mainstay Medical

Emergency Medicine
Health Care
Medical Device
$108M16 Feb 2021 Ireland, Dublin

Neurent Medical

Health Care
Medical Device
Surgical Devices
Therapeutic Devices
$24M20 Jan 2021 Ireland, " Ireland"}

Neuromod Devices

Clinical Trials
Health Care
Medical Device
$12M20 Oct 2020 Ireland, Dublin


Health Care
$35M12 Oct 2020 Ireland, Dublin


Health Care
$5M11 Feb 2020 France, Paris

Neuromod Devices

Clinical Trials
Health Care
Medical Device
$9M26 Sep 2019 Ireland, Dublin

Velicept Therapeutics

Health Care
$15M16 Oct 2018 United States, " United States"}

KaNDy Therapeutics

Health Care
$34M29 Aug 2018 United Kingdom, " United Kingdom"}
XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease

– XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in advanced coronary artery disease, today announced the closing of an additional $22.6 million financing.
Fountain Healthcare Partners led the oversubscribed financing joined by new investors Longwood Fund and Lumira Ventures. All existing institutional investors including Sofinnova Investments and LSP (Life Sciences Partners) participated in the financing.
– The additional financing builds upon XyloCor’s 2018 Series A financing round, bringing total investment in the company to $41.9 million to date.

Mainstay Medical Receives US$108M Equity Financing

– Mainstay Medical Holdings, a Dublin, Ireland-based medical device company focused on commercializing an innovative implantable restorative neurostimulation system for people with disabling mechanical Chronic Low Back Pain, closed an equity financing of US$108m.
– The round was co-led by new investors Ally Bridge Group and Sofinnova Partners, through its Crossover Fund, and also included a large, global medical device company.
– Key existing investors participating include Sofinnova Partners (Capital Fund), KCK Group and Fountain Healthcare Partners.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Fountain Healthcare Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: